SCN1A, ABCC2 and UGT2B7 gene polymorphisms in association with individualized oxcarbazepine therapy

Pharmacogenomics

Volumn 16, Issue 4, 2015, Pages 347-360

  Ma, Chun Lai ^a   Wu, Xun Yi ^a   Jiao, Zheng ^a   Hong, Zhen ^a   Wu, Zhi Yuan ^a   Zhong, Ming Kang ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

ABCC2; epilepsy; genetic polymorphisms; oxcarbazepine; SCN1A; SCN2A; UGT2B7

Indexed keywords

ADENOSINE; GUANIDINE; OXCARBAZEPINE;

ABCC2 GENE; ALLELE; ANTICONVULSANT THERAPY; ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG RESPONSE; EPILEPSY; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACOGENETICS; SCN1A GENE; SCN2A GENE; SINGLE NUCLEOTIDE POLYMORPHISM; UGT2B7 GENE;

EID: 84964301737     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.186     Document Type: Article

References (57)

1. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav. 5(5), 627-635 (2004).
2. Loscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 50(1), 1-23 (2009).
3. Wellington K, Goa KL. Oxcarbazepine: An update of its efficacy in the management of epilepsy. CNS Drugs 15(2), 137-163 (2001).
4. Guillemette C. Pharmacogenomics of human UDPglucuronosyltransferase enzymes. Pharmacogenomics J. 3(3), 136-158 (2003).
5. Bhasker CR, McKinnon W, Stone A et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10(8), 679-685 (2000).
6. Lin GF, Guo WC, Chen JG et al. An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China. Toxicol. Sci. 85(1), 502-506 (2005).
7. Begley DJ. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 10(12), 1295-1312 (2004).
8. Sisodiya SM, Thom M. Widespread upregulation of drugresistance proteins in fatal human status epilepticus. Epilepsia 44(2), 261-264 (2003).
9. Loscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6(8), 591-602 (2005).
10. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12(16), 3557-3560 (2001).
11. Loscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharmacol. Exp. Ther. 301(1), 7-14 (2002).
12. Haerian BS, Roslan H, Raymond AA et al. ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: A systematic review and meta-analysis. Seizure 19(6), 339-346 (2010).
13. Bournissen FG, Moretti ME, Juurlink DN, Koren G, Walker M, Finkelstein Y. Polymorphism of the MDR1/ABCB1 C3435T drug-transporter and resistance to anticonvulsant drugs: A meta-analysis. Epilepsia 50(4), 898-903 (2009).
14. Nurmohamed L, Garcia-Bournissen F, Buono RJ, Shannon MW, Finkelstein Y. Predisposition to epilepsy-does the ABCB1 gene play a role? Epilepsia 51(9), 1882-1885 (2010).
15. Kim WJ, Lee JH, Yi J et al. A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy. Pharmacogenet. Genomics 20(4), 249-256 (2010).
16. Grover S, Gourie-Devi M, Bala K, Sharma S, Kukreti R. Genetic association analysis of transporters identifies ABCC2 loci for seizure control in women with epilepsy on firstline antiepileptic drugs. Pharmacogenet. Genomics 22(6), 447-465 (2012).
17. Qu J, Zhou BT, Yin JY et al. ABCC2 polymorphisms and haplotype are associated with drug resistance in Chinese epileptic patients. CNS Neurosci. Ther. 18(8), 647-651 (2012).
18. Seo T, Ishitsu T, Oniki K, Abe T, Shuto T, Nakagawa K. ABCC2 haplotype is not associated with drug-resistant epilepsy. J. Pharm. Pharmacol. 60(5), 631-635 (2008).
19. Kim DW, Lee SK, Chu K et al. Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res. 84(1), 86-90 (2009).
20. Kwan P, Wong V, Ng PW et al. Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics 12(3), 319-325 (2011).
21. Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv. Drug Deliv. Rev. 64(10), 930-942 (2012).
22. Potschka H, Fedrowitz M, Loscher W. Multidrug resistance protein MRP2 contributes to blood-brain barrier function and restricts antiepileptic drug activity. J. Pharmacol. Exp. Ther. 306(1), 124-131 (2003).
23. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'Giano C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 48(Suppl. 5), 140-149 (2007).
24. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, Carvalho AP. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem. Res. 27(1-2), 121-130 (2002).
25. Ragsdale DS. How do mutant Nav1.1 sodium channels cause epilepsy? Brain Res. Rev. 58(1), 149-159 (2008).
26. Catterall WA, Goldin AL, Waxman SG. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels. Pharmacol. Rev. 57(4), 397-409 (2005).
27. Tate SK, Depondt C, Sisodiya SM, Cavallert GL, Schorge S. Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. PNAS 102(15), 5507-5512 (2005).
28. Tate SK, Singh R, Hung CC et al. A common polymorphism in the SCN1A gene associations with phenytoin serum levels at maintenance dose. Pharmacogenet. Genomics 16(10), 721-726 (2006).
29. Hung CC, Chang WL, Ho JL et al. Association of polymorphisms in EPHX1, UGT2B7, ABCB1, ABCC2, SCN1A and SCN2A genes with carbamazepine therapy optimization. Pharmacogenomics 13(2), 159-169 (2012).
30. Abe T, Seo T, Ishitsu T, Nakagawa T, Hori M, Nakagawa K. Association between SCN1A polymorphism and carbamazepine-resistant epilepsy. Br. J. Clin. Pharmacol. 66(2), 304-307 (2008).
31. Zimprich F, Stogmann E, Bonelli S et al. A functional polymorphism in the SCN1A gene is not associated with carbamazepine dosages in Austrian patients with epilepsy. Epilepsia 49(6), 1108-1109 (2008).
32. Manna I, Gambardella A, Bianchi A et al. A functional polymorphism in the SCN1A gene does not influence antiepileptic drug responsiveness in Italian patients with focal epilepsy. Epilepsia 52(5), e40-e44 (2011).
33. Kumari R, Lakhan R, Kumar S et al. SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness. Biochimie 95(6), 1350-1353 (2013).
34. Lakhan R, Kumari R, Misra UK, Kalita J, Pradhan S, Mittal B. Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population. Br. J. Clin. Pharmacol. 68(2), 214-220 (2009).
35. Kwan P, Poon WS, Ng HK et al. Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression. Pharmacogenet. Genomics 18(11), 989-998 (2008).
36. Zhou BT, Zhou QH, Yin JY et al. Comprehensive analysis of the association of SCN1A gene polymorphisms with the retention rate of carbamazepine following monotherapy for new-onset focal seizures in the Chinese Han population. Clin. Exp. Pharmacol. Physiol. 39(4), 379-384 (2012).
37. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 30(4), 389-399 (1989).
38. Kwan P, Arzimanoglou A, Berg AT et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51(6), 1069-1077 (2010).
39. Ma C, Jiao Z, Jie Y, Shi X. Isocratic Reversed-Phase HPLC for Simultaneous separation and determination of seven antiepileptic drugs and two of their active metabolites in human plasma. Chromatographia 65(5-6), 267-275 (2007).
40. Power and sample size software by USC Biostats. http://biostats.usc.edu/software
41. SHEsis online software. http://analysis.bio-x.cn/myAnalysis.php
42. Ma L, Ballantyne C, Brautbar A, Keinan A. Analysis of multiple association studies provides evidence of an expression QTL hub in gene-gene interaction network affecting HDL cholesterol levels. PLoS ONE 9(3), e92469 (2014).
43. The R Project for Statistical Computing. www.r-project.org
44. Zhou BT, Zhou QH, Yin JY et al. Effects of SCN1A and GABA receptor genetic polymorphisms on carbamazepine tolerability and efficacy in Chinese patients with partial seizures: 2-year longitudinal clinical follow-up. CNS Neurosci. Ther. 18(7), 566-572 (2012).
45. Heinzen EL, Yoon W, Tate SK et al. Nova2 interacts with a cis-acting polymorphism to influence the proportions of drug-responsive splice variants of SCN1A. Am. J. Hum. Genet. 80(5), 876-883 (2007).
46. Fletcher EV, Kullmann DM, Schorge S. Alternative splicing modulates inactivation of type 1 voltage-gated sodium channels by toggling an amino acid in the first S3-S4 linker. J. Biol. Chem. 286(42), 36700-36708 (2011).
47. Thompson CH, Kahlig KM, George AJ. SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs. Epilepsia 52(5), 1000-1009 (2011).
48. Ufer M, von Stulpnagel C, Muhle H et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet. Genomics 21(10), 624-630 (2011).
49. Hilger E, Reinthaler EM, Stogmann E et al. Lack of association between ABCC2 gene variants and treatment response in epilepsy. Pharmacogenomics 13(2), 185-190 (2012).
50. Carrier JS, Turgeon D, Journault K, Hum DW, Belanger A. Isolation and characterization of the human UGT2B7 gene. Biochem. Biophys. Res. Commun. 272(2), 616-621 (2000).
51. Ritter JK, Sheen YY, Owens IS. Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. 3,4-catechol estrogens and estriol as primary substrates. J. Biol. Chem. 265(14), 7900-7906 (1990).
52. Holthe M, Klepstad P, Zahlsen K et al. Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1 28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol. 58(5), 353-356 (2002).
53. Guo Y, Hu C, He X, Qiu F, Zhao L. Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in Chinese children with epilepsy. Drug Metab. Pharmacokinet. 27(5), 536-542 (2012).
54. Sawyer MB, Innocenti F, Das S et al. A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73(6), 566-574 (2003).
55. Chung JY, Cho JY, Yu KS et al. Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin. Pharmacol. Ther. 83(4), 595-600 (2008).
56. Jang SY, Kim MK, Lee KR et al. Gene-to-gene interaction between sodium channel-related genes in determining the risk of antiepileptic drug resistance. J. Korean Med. Sci. 24(1), 62-68 (2009).
57. Gonzalez-Esquivel DF, Ortega-Gavilan M, Alcantara-Lopez G, Jung-Cook H. Plasma level monitoring of oxcarbazepine in epileptic patients. Arch. Med. Res. 31(2), 202-205 (2000).